CeriBell (NASDAQ:CBLL) Now Covered by Canaccord Genuity Group

Canaccord Genuity Group assumed coverage on shares of CeriBell (NASDAQ:CBLL) in a research note issued to investors on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $30.00 target price on the stock.

Several other equities research analysts have also recently weighed in on CBLL. TD Cowen assumed coverage on shares of CeriBell in a research report on Tuesday. They issued a “buy” rating and a $31.00 price target on the stock. William Blair assumed coverage on CeriBell in a research report on Tuesday. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. started coverage on CeriBell in a research report on Tuesday. They set an “overweight” rating and a $32.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $31.00.

CeriBell Stock Performance

NASDAQ CBLL opened at $26.96 on Tuesday. CeriBell has a 1-year low of $23.00 and a 1-year high of $27.71.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.